Prosight Management, L.P. 13F annual report
Prosight Management, L.P. is an investment fund managing more than $335 billion ran by Ryan Cappelli. There are currently 46 companies in Mr. Cappelli’s portfolio. The largest investments include Galapagos NV and ADC Therapeutics SA, together worth $63.7 billion.
$335 billion Assets Under Management (AUM)
As of 7th August 2024, Prosight Management, L.P.’s top holding is 1,349,980 shares of Galapagos NV currently worth over $33.5 billion and making up 10.0% of the portfolio value.
Relative to the number of outstanding shares of Galapagos NV, Prosight Management, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 9,570,000 shares of ADC Therapeutics SA worth $30.2 billion, whose value fell 42.2% in the past six months.
The third-largest holding is Roivant Sciences Ltd worth $21.1 billion and the next is BridgeBio Pharma Inc worth $20.3 billion, with 800,000 shares owned.
Currently, Prosight Management, L.P.'s portfolio is worth at least $335 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Prosight Management, L.P.
The Prosight Management, L.P. office and employees reside in Dallas, Texas. According to the last 13-F report filed with the SEC, Ryan Cappelli serves as the Chief Compliance Officer/Chief Operating Officer at Prosight Management, L.P..
Recent trades
In the most recent 13F filing, Prosight Management, L.P. revealed that it had opened a new position in
Roivant Sciences Ltd and bought 2,000,000 shares worth $21.1 billion.
The investment fund also strengthened its position in Galapagos NV by buying
522,686 additional shares.
This makes their stake in Galapagos NV total 1,349,980 shares worth $33.5 billion.
Galapagos NV dropped 37.7% in the past year.
On the other hand, there are companies that Prosight Management, L.P. is getting rid of from its portfolio.
Prosight Management, L.P. closed its position in Oric Pharmaceuticals on 14th August 2024.
It sold the previously owned 1,578,263 shares for $14.5 billion.
Ryan Cappelli also disclosed a decreased stake in Kura Oncology Inc by 0.3%.
This leaves the value of the investment at $13 billion and 629,900 shares.
One of the smaller hedge funds
The two most similar investment funds to Prosight Management, L.P. are Sws Partners and El Puerto De Liverpool, S.a.b. De C.v. They manage $335 billion and $334 billion respectively.
Ryan Cappelli investment strategy
Prosight Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 74.7% of
the total portfolio value.
The fund focuses on investments in the United States as
56.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
11% of the total holdings value.
On the other hand, small-cap stocks make up only 4.3% of the portfolio.
The average market cap of the portfolio companies is close to $10.5 billion.
The complete list of Prosight Management, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Galapagos NV |
63.18%
1,349,980
|
$33,452,504,000 | 10.00% |
| ADC Therapeutics SA |
47.87%
9,570,000
|
$30,241,200,000 | 9.04% |
| Roivant Sciences Ltd |
Opened
2,000,000
|
$21,140,000,000 | 6.32% |
| BridgeBio Pharma Inc |
Opened
800,000
|
$20,264,000,000 | 6.06% |
| Zimmer Biomet Holdings Inc |
Opened
170,000
|
$18,450,100,000 | 5.51% |
| Meiragtx Hldgs Plc |
7.46%
4,352,700
|
$18,324,867,000 | 5.48% |
| Shattuck Labs, Inc. |
67.82%
4,670,000
|
$18,026,200,000 | 5.39% |
| Oric Pharmaceuticals, Inc. |
Closed
1,578,263
|
$14,520,020,000 | |
| Kura Oncology Inc |
33.69%
629,900
|
$12,969,641,000 | 3.88% |
| Cytokinetics Inc |
Opened
230,000
|
$12,461,400,000 | 3.72% |
| Syndax Pharmaceuticals Inc |
Opened
551,544
|
$11,323,198,000 | 3.38% |
| Mirum Pharmaceuticals Inc |
7.33%
314,800
|
$10,763,012,000 | 3.22% |
| Kelly Svcs Inc |
Opened
492,340
|
$10,540,999,000 | 3.15% |
| Zymeworks Inc |
Opened
1,180,000
|
$10,041,800,000 | 3.00% |
| QuidelOrtho Corporation |
Closed
118,920
|
$8,764,404,000 | |
| Pacira BioSciences Inc |
Closed
258,424
|
$8,719,226,000 | |
| Immunovant Inc |
Opened
325,000
|
$8,580,000,000 | 2.56% |
| Schrodinger, Inc. |
Opened
369,261
|
$7,141,508,000 | 2.13% |
| AbCellera Biologics Inc. |
38.39%
2,352,633
|
$6,963,794,000 | 2.08% |
| Alkermes plc |
1,733.33%
275,000
|
$6,627,500,000 | 1.98% |
| Erasca Inc |
358.75%
2,750,000
|
$6,490,000,000 | 1.94% |
| Viking Therapeutics Inc |
Opened
115,000
|
$6,096,150,000 | 1.82% |
| Prothena Corp Plc |
25.00%
286,926
|
$5,922,153,000 | 1.77% |
| OrthoPediatrics corp |
110.75%
200,216
|
$5,758,212,000 | 1.72% |
| Option Care Health, Inc. |
37.77%
205,000
|
$5,678,500,000 | 1.70% |
| Dexcom Inc |
114.42%
49,317
|
$5,591,561,000 | 1.67% |
| Accolade, Inc. |
Opened
1,489,525
|
$5,332,500,000 | 1.59% |
| Cogent Biosciences, Inc. |
Opened
500,000
|
$4,215,000,000 | 1.26% |
| Neurocrine Biosciences, Inc. |
24.79%
27,000
|
$3,717,090,000 | 1.11% |
| Graphite Bio |
Closed
1,351,939
|
$3,542,080,000 | |
| Nuvation Bio Cl A |
Closed
2,050,000
|
$3,095,500,000 | |
| Relay Therapeutics, Inc. |
Opened
385,000
|
$2,510,200,000 | 0.75% |
| Biocryst Pharmaceuticals Inc. |
82.14%
398,700
|
$2,463,966,000 | 0.74% |
| CVS Health Corp |
Opened
40,000
|
$2,362,400,000 | 0.71% |
| Medtronic Plc |
86.36%
30,000
|
$2,361,300,000 | 0.71% |
| Vincerx Pharma Inc |
Opened
2,488,418
|
$2,015,619,000 | 0.60% |
| Veradigm Inc |
Closed
180,000
|
$1,888,200,000 | |
| Inspire Med Sys Inc |
Opened
14,000
|
$1,873,620,000 | 0.56% |
| Paragon 28, Inc. |
Opened
261,400
|
$1,787,976,000 | 0.53% |
| Universal Hlth Svcs Inc |
66.63%
9,373
|
$1,733,349,000 | 0.52% |
| Privia Health Group Inc |
27.31%
96,065
|
$1,669,610,000 | 0.50% |
| Barrett Business Services Inc. |
Closed
13,000
|
$1,505,400,000 | |
| Mural Oncology Pub Ltd Co |
13.61%
475,458
|
$1,492,938,000 | 0.45% |
| Addus HomeCare Corporation |
Opened
12,500
|
$1,451,375,000 | 0.43% |
| Spyre Therapeutics |
Closed
55,000
|
$1,183,600,000 | |
| Tectonic Therapeutic Inc |
Opened
67,461
|
$1,111,083,000 | 0.33% |
| Lenz Therapeutics Inc |
Opened
59,542
|
$1,029,481,000 | 0.31% |
| 10x Genomics, Inc. |
Opened
49,021
|
$953,458,000 | 0.28% |
| Shockwave Medical Inc. |
Closed
5,000
|
$952,800,000 | |
| Ovid Therapeutics Inc |
Opened
1,075,000
|
$826,890,000 | 0.25% |
| Immunome, Inc. |
Opened
65,000
|
$786,500,000 | 0.24% |
| Design Therapeutics |
Closed
280,000
|
$742,000,000 | |
| Aileron Therapeutics Inc |
Opened
265,000
|
$734,050,000 | 0.22% |
| Immuneering Corp |
Opened
550,000
|
$704,000,000 | 0.21% |
| Biomea Fusion Inc |
189.31%
124,377
|
$559,697,000 | 0.17% |
| Kezar Life Sciences Inc |
98.33%
56,080
|
$33,648,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 56 holdings | |||
Hedge funds similar to Prosight Management, L.P.
- Mccollum Christoferson
- Humankind Investments
- Medicxi Ventures Management (jersey) Ltd
- Smith & Howard Wealth Management
- Root Partners
- Chan Zuckerberg Initiative
- Old Port Advisors
- Sws Partners
- El Puerto De Liverpool, S.a.b. De C.v
- Kiley Juergens Wealth Management
- Cornerstone Wealth Advisors
- Evergreen Advisors
- Birinyi Associates Inc
- Petix & Botte Co